Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|---|---|---|---|---|---|---|---|
Delteil 2024 |
France 2004 - 2021 retrospective cohort (claims database) |
EFEMERIS (Évaluation chez la Femme Enceinte des MÉdicaments et de leurs RISques) database, and the Registre des Handicaps de l'Enfant en Haute-Garonne (RHE31), Haute-Garonne, France. | Pregnancies with at least one dispensed prescription of Betaxolol during pregnancy (between last menstrual period and delivery). |
unexposed (general population or NOS)
Pregnancies without dispensed prescription of beta-blockers and other anti-hypertensive agents during pregnancy. |
at least 1st trimester | 7 / 172284 | When available, data in women with chronic pathology (hypertension or cardiac), treated at least during the 1st trimester were preferred to all indications (including gestational hypertension, ...). Exposure at least T1 considered as chronic indications. | |
Women's drug exposure during pregnancy was estimated on the basis of dispensed prescription drugs recorded by the French Assurance Maladie. | ||||||||
Vaclavik 2024 |
The Czech Republic 2012 - 2022 population based cohort retrospective |
The National Registry of Reproductive Health (NRRZ) and the National Registry of Reimbursable Health Services (NRHZS). | Births whose mothers were prescribed Betaxalol during pregnancy (for pre-existing hypertension or pregnancy-induced hypertension). |
unexposed, disease free
Births whose mothers had no hypertension. |
during pregnancy (anytime or not specified) | -9 / -9 | ||
The National Registry of Reimbursable Health Services (NRHZS). |
Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;